European Society for Translational Medicine (EUSTM)
01 September 2015 - 04 September 2015
EUSTM-2015 will discuss and showcase latest developments in specific areas of cellular & molecular biology, omics sciences, data mining and management, disease modeling, biomarkers & novel diagnostics and public health. The conference will unite scientists, clinicians, world leaders and experts from research institutions, industry, regulatory agencies, policy makers, and governments.
EUSTM-2015 provides the key to future success in global healthcare by addressing current challenges and by highlight novel solutions. The conference represents a unique opportunity for global networking with key opinion leaders and service providers. Participants will also include practicing physicians with clinical experience in various therapeutic areas and members of patient organizations. Pharmaceutical and biotech industries, medtech and medical instruments companies, consultancy firms, clinical research organizations and data management companies will showcase and exhibit their products and services.
Schönbrunn Palace Conference Centre, Vienna, Austria
http://www.eutranslationalmedicine.org/eustm-2015
Professional Certification in Translational Medicine (PCTM)
04 September 2015 - 04 September 2015
Professional Certification in Translational Medicine (PCTM) program is designed by the Academy of Translational Medicine Professionals (ATMP) to set the standards for excellence in field of translational medicine and to promote and maintain high quality in clinical research
Program Accreditation
Professional Certification in Translational Medicine (PCTM) program is accredited by the European Society for Translational Medicine (EUSTM). After certification approval, successful individuals may use the title (PCTM). Certification is valid for two years from date of certification approval. Certification renewal application can be made after two years.
Certification Benefits
- Increased Job Opportunities
Professional certification will increase your job opportunities and accelerate your promotions by highlighting you from other colleagues and pool of other candidates.
- Stay-Up-To-Date
Professional certification will ensure translational medicine knowledge and skills are up to date.
- Show Your Competency
Professional certification will show your competency to conduct and manage translational research studies.
- Demonstrate Your Commitment
Professional certification demonstrates your commitment to the advancement of clinical research.
Falkensteiner Hotel Wien Margareten Vienna, Austria
http://www.eutranslationalmedicine.org/pctm
2nd Cell & Gene Therapy Conference
09 September 2015 - 10 September 2015
We invite you to attend the 2nd Cell & Gene Therapy Conference, which will take place September 9-10, 2015 in Philadelphia, PA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues and gain fresh perspective on the various research.
Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones.
Session Topics:
I. Emerging Technologies & Pre-clinical Research
II. Clinical Development
III. Strategies for Commercialization
IV. Regulatory Challenges
V. Funding/Finance for Cell & Gene Therapy
Loews Philadelphia Hotel, Philadelphia, PA, USA
https://www.gtcbio.com/conferences/cell-gene-therapy-overview
2nd Biotechnology Transfer & Commercialization Conference
09 September 2015 - 10 September 2015
GTCbio’s 2nd Biotechnology Transfer & Commercialization Conference which will take place September 9-10, 2015 in Philadelphia, PA, will bring together the players needed to move the industry forward. Leading universities, pharmaceutical companies, venture capital, foundations and biotech companies will come together to share their perspectives, discuss new models of cooperation and develop the business relationships that get deals done. Together they will create new technologies, new companies and new medicines.
tbc Philadelphia, PA, USA
https://www.gtcbio.com/conferences/biotechnology-transfer-commercialization-overview?utm_source=biotechtransfer&utm_medium=eventlisting&utm_campaign=eventlink
8th CNS Partnering & Deal-Making Conference
10 September 2015 - 11 September 2015
We are pleased to announce GTCbio's 4th Influenza Research & Development Conference, which will take place July 8-10, 2015 in Boston, MA.
This meeting seeks to create a forum to discuss emerging viruses such as H7N9 and MERS CoV, as well as updates on new breakthroughs in current viruses. Colleagues will discuss questions such as what is the role of the microbiome on influenza? Is finding a universal treatment for flu still relevant? In addition to scientific presentations, colleagues will form connections and build relationships during dedicated networking times.
Loews Philadelphia Hotel, Philadelphia, PA, USA
https://www.gtcbio.com/conferences/cns-partnering-deal-making-overview
Analytics for Biologics Conference
10 September 2015 - 11 September 2015
We are please to invite you to GTCbio's Analytics for Biologics Conference on September 10-11, 2015 in Philadelphia, PA. This meeting will provide the tools and the strategies needed to stay ahead in the ever changing and evolving field of biologics. Join this multi-disciplinary forum and network with colleagues from industry and academia to discuss analytical methods and tools that will ensure the most efficient and accurate optimization of biologics.
Experts from government agencies and big pharma will introduce the approaches that are necessary to tackle the challenges in regulations and standards through well calculated analytics and strategies.
Session Topics:
I. Regulatory Standards & Managing Risk
II. Bioconjugates & Antibody Drug Conjugates
III. Biotherapeutic Proteins & Sequence Variants
IV. Cell Therapeutics & Immunotherapy
V. Comparability & Biosimilarity
VI. Methodology, Tools & Strategies
• Process Analytics
• Release, Stability Testing Methods & Specification
• Critical Quality Attributes & Characterization
• Potency Assays & Clinical Assays
• Challenges with Validation
Loews Philadelphia Hotel, Philadelphia, PA, USA
https://www.gtcbio.com/conferences/analytics-biologics-overview?utm_source=afb&utm_medium=EventListing&utm_campaign=overview
Cancer Vaccines
16 September 2015 - 17 September 2015
Cancer Vaccines are medicines that boost the immune’s natural ability to protect the body against “foreign invaders,” mainly infectious agents that may cause disease as opposed to chemotherapy and radiotherapy that utilize chemical drugs and radiation, respectively.
Increased knowledge in our immune system has opened up new combination therapies in immuno-oncology, to enhance immune response to vaccines. Thus, some new treatments include use of monoclonal antibodies and genetically engineered viral vectors to kill tumours.
Research is rapidly growing in targeted immuno-therapy, involving treatment in the form of peptide vaccines (T and B cell epitopes), DNA vaccines and vaccination using dendritic cells, viral vectors, antibodies and adoptive transfer of T cells.
However, it has also become clear that cancer cells have different ways of eluding the immune system, which makes creating effective vaccines difficult. Thus, vaccines are now often given along with other substances (called adjuvants) that help boost the body’s immune response, which might help the vaccines work better.
Researchers are also studying the best way to give vaccines, looking to see if they work better when used alone or with other types of cancer treatments.
Marriott Hotel, Regents Park, London, UK
https://www.smi-online.co.uk/pharmaceuticals/uk/conference/cancer-vaccines
Biosimilars and Biobetters
30 September 2015 - 01 October 2015
With Europe leading the way in the field of Biosimilar development, it is important to get to grips with all areas in the product lifecycle from early stage developments, protein characterisation and analytical comparability to patent litigation, market access, pricing and reimbursement through to emerging markets and global developments. Every angle should be considered and taken account for through the development process and with the EU the most advanced market for biosimilars, accounting for 80% of global spending on these molecules, the learning curve for biosimilars is essentially still building and there are hurdles to overcome.
Holiday Inn, Kensington Forum, London, UK
https://www.smi-online.co.uk/pharmaceuticals/uk/conference/biosimilars-and-biobetters